Purine metabolism has been examined in a clonil line of mouse neuroblastoma cells resistant to the cytotoxic effects of 6-thioguanine. Comparative studies in the resistant and parental lines indicate that the former cells have less than 1% of normal hypoxanthine phosphoribosyltransferase (EC 2.4.2.8) activity. The activities of other enzymes important in the de novo and salvage pathways of purine biosynthesis were not significantly different in the two lines. Hypoxanthine phosphoribosyltransferase deficiency in this neuroblastoma line was associated with increased intracellular concentrations of 5-phosphoribosyl-
cells have less than 1% of normal hypoxanthine phosphoribosyltransferase (EC 2.4.2.8) activity. The activities of other enzymes important in the de novo and salvage pathways of purine biosynthesis were not significantly different in the two lines. Hypoxanthine phosphoribosyltransferase deficiency in this neuroblastoma line was associated with increased intracellular concentrations of 5-phosphoribosyl-I-pyrophosphate, an increased rate of purine biosynthesis de novo, and failure to incorporate hypoxanthine, but not adenine, into nucleotides. There are essentially the same alterations in purine metabolism that occur in hypoxanthine phosphoribosyltransferase-deficient fibroblasts or lymphoblasts derived from individuals with the LeschNyhan syndrome. Clonal lines of hypoxanthine phosphoribosyltransferase-deficient neuroblastoma cells may therefore be of use in elucidating the mechanisms by which the enzyme defect leads to the neurologic dysfunction seen in children with this disease.
The Lesch-Nyhan syndrome (1) is a rare, X-linked disease whose primary biochemical defect is a severe deficiency of hypoxanthine phosphoribosyltransferase (HPRT) (EC 2.4.2.8) activity (2) . This enzyme deficiency results in a characteristic increase in rate of purine nucleotide synthesis in fibroblasts (3) and lymphoblasts (4) derived from these patients. In addition to abnormal metabolism of purines, patients with the Lesch-Nyhan syndrome exhibit in varying degrees severe neurological abnormalities characterized by mental retardation, spasticity, choreoathetosis, and compulsive self-mutilation. The HPRT and adenine phosphoribosyltransferase (APRT) (EC 2.4.2.7) activities were determined in the cell-free ex-tracts by a described (4) modification of the method of Fujimoto and Seegmiller (14) . Glutamine phosphoribosyl pyrophosphate amidotransferase (PP-ribose-P amidotransferase) (EC 2.4.2.14) activity was assayed by determining the PPribose-P-dependent hydrolysis of glutamine to glutamic acid by the method of Martin (15) described in detail elsewhere (4) . PP-Ribose-P synthetase (EC 2.7.6.1) activity was determined by a described modification (4) of the two-step procedure of Hershko et al. (16) . For this assay, the cells were washed and disrupted as described above except that the final buffer was 15 mM sodium phosphate, pH 7.4, with 5 mM reduced glutathione and 1 mM EDTA.
Estimation of the Rate of de novo Purine Synthesis. [8-14C] adenine (60 mCi/mmol) for 60 min at 37°. The reaction was then terminated by the addition of 20 ,l of 42% perchloric acid (0°). After 10 min at 00, 30 Ml of 4.45 M KOH was added to neutralize the reaction mixture and the precipitate was removed by centrifugation at 1200 X g. An aliquot of the supernatant fluid was applied to sheets of polyethyleneimine-cellulose and developed in methanol-water (50:50 v/v) for 16 hr, as described by Crabtree and Henderson (18) . The purine nucleotides that remained at the origin were cut out and counted for radioactivity without further resolution. RESULTS HPRT Activity. Fig. 1 shows the relationship between HPRT activity and protein concentration and time of incubation in cell-free extracts of the parental (N4) and thioguanineresistant (N4TG1) cell lines. Under the assay conditions described, inosinic acid formation in lysates of normal cells was proportional to protein concentration up to 100 Mg of protein and to incubation time for at least 50 min. The specific activity of HPRT in the N4 line was 200 nmol/hr per mg of protein, while enzyme activity of N4TG1 cells grown in the absence of 6-SGua for at least 72 hr was less than 1% of this value.
When extracts from parental and 6-SGua-resistant lines were mixed, neither an inhibitor of HPRT activity in N4TG1 cell extracts nor an activator of enzyme activity in the N4 cell extract was detected. Other Enzymes of Purine Synthesis. APRT catalyzes the formation of AMP from adenine and PP-ribose-P by a reaction analogous to the HPRT reaction. PP-Ribose-P is also a substrate for glutamine PP-ribose-P amidotransferase, the first and presumed rate-limiting reaction of de novo purine biosynthesis. PP-Ribose-P itself is synthesized from ATP and ribose-5-phosphate by PP-ribose-P synthetase. Table 1 illustrates the specific activities of these enzymes in N4 and N4 TG1 cell extracts. Except for the loss of HPRT activity, thioguanine-resistant cells showed no significant alterations in the enzyme activities examined.
Intracellular PP-Ribose-P Concentration and Rate of Initial Reactions of de novo Purine Biosynthesis in Intact Cells. Previous studies in fibroblasts (3) and lymphoblasts (4) have shown that loss of HPRT activity is associated with an increased intracellular concentration of PP-ribose-P and an increased rate of purine biosynthesis de novo. The data in Table 2 show that N4TG1 cells deficient in HPRT have a five-fold elevation in PP-ribose-P concentration and an almost three-fold increase in FGAR synthesis. Addition of hypoxanthine to the incubation mixture in a final concentration of 1 X 10-4 M results in a 40% inhibition of FGAR synthesis in N4 cells, but no significant change in FGAR synthesis in N4TG1 cells. Adenine at the same concentration completely suppresses FGAR synthesis in both cell lines. Purine base inhibition of de novo purine biosynthesis is presumably mediated through inhibition of PP-ribose-P amidotransferase by the nucleotide form of the purine base and by depletion of intracellular PP-ribose-P. The loss of HPRT activity in the thioguanine-resistant cells thus explains the failure of hypoxanthine to inhibit FGAR production.* Purine Base Incorporation into Nucleotides. A direct assessment of the relative abilities of N4 and N4TG1 cells to form acid-soluble nucleotides from purine-bases is shown in Table  2 . Adenine uptake and incorporation into total nucleotide in N4TG1 is 90% of that found in the parental line (C, Table 2 ), while incorporation of hypoxanthine into nucleotide is less than 1% of that in the parental line (D, Table 2 ). The marked deficit in the ability of the HPRT-deficient cells to incorporate hypoxanthine into nucleotide provides a functional demonstration of the basis of their resistance to the toxic effects of 6-SGua which is converted to the pharmacologically active nucleotide by HPRT. The 10% difference in adenine incorporation in N4 and N4TG1 cells may be due to the breakdown of labeled AMP to hypoxanthine [by way of adenosine and inosine (19) ] and the inability of HPRT-deficient cells to reutilize the base for nucleotide formation.
DISCUSSION
While HPRT is distributed throughout the body, the highest levels of enzyme activity are found in the brain, particularly in the basal ganglia, where levels are ten-fold higher than in other tissues (20, 21) . HPRT A. Cells were harvested and washed twice in fresh DME medium. Immediately before immersion in a 980 water bath for 45 sec, cells were collected by centrifugation and resuspended in 0.3 ml of 50 mM Tris-HCl, 1 mM EDTA, pH 7.4. PP-ribose-P was determined as described (4) . Values represent the average of five replicate determinations.
B. Rate of [8-14C] formate incorporation into FGAR was determined in cells washed twice in fresh DME and resuspended in a final volume of 0.6 ml which contained 6 X 105 neuroblastoma cells in 0.5 ml fresh DME, 150 ,ug glycine, 30 pig azaserine, and 0.42, pmol sodium [14C]formate (56 mCi/mmol). All reagents were dissolved in DPBS. Incubation at 370 was for 60 min.
C. and D. Purine nucleotide synthesis from labeled adenine or hypoxanthine was determined as described in Experimental Procedures.
the Lesch-Nyhan syndrome as well as from two affected fetuses (21) (22) (23) . Despite the severe impairment of neurological function in affected individuals, no distinctive morphologic or histologic changes in the central nervous system have been observed, and the role of HPRT in normal neuronal function
is not yet understood. Three subpopulations of HPRT-deficient individuals can be identified on the basis of neurological impairment. The most severe deficiencies of HPRT activity result in the classic neurological features of the Lesch-Nyhan syndrome. Individuals with 1% or more of normal erythrocyte HPRT activity have no apparent neurological abnormalities, but exhibit excessive production of uric acid. An intermediate group possesses some neurological abnormalities, varying from individual to individual. The extent of neurological impairment is inversely related to the residual HPRT activity (20) .
Girls heterozygous for this X-linked defect have no neurological manifestations despite the predicted enzyme absence in that fraction of cells undergoing X inactivation of the chromosome bearing the normal allele (24) . If Proc. Nat. Acad. Sci. USA 70 (1973) neuronal cells has been found, an analogous loss of HPRTdeficient precursors of hematopoietic cells has been proposed to account for the normal content of HPRT generally found in erythrocytes and lymphocytes from girls heterozygous for severe HPRT deficiency (27, 28) . Since the two populations of cells predicted by the random inactivation of one of the two X chromosomes in women by the Lyon Hypothesis (24) are present in fibroblasts (29) (30) (31) and hair follicles (32-34) of heterozygous women, the selective loss of HPRT-deficient cells occurs only in certain tissues.
A major question in understanding the pathophysiology of the Lesch-Nyhan syndrome is whether the enzyme defect must be expressed within the nervous system (autonomous) or in some other organ system. A related question is whether the defect must be expressed in neurons or glia, either one or both cell types. Because human nervous system material is difficult to obtain, two general experimental approaches are possible. First, induction of the mutation in whole animals, either vertebrate [e.g., mouse as recently outlined by DeMars (35)] or invertebrate (e.g., drosophilia), would appear useful. The use of gynandromorphs would appear particularly well suited to the study of the autonomy of the defect (36) . Second, culture of nervous tissue either from patients bearing the defect, or of specially created mutant neural and glial lines is possible. This paper reports a mutant mouse neuroblastoma line (N4TG1), deficient in HPRT, that was selected by virtue of resistance to 6-SGua. In addition to a deficiency of HPRT, the mutant line is characterized biochemically by increased intracellular PP-ribose-P concentration, an increased rate of purine biosynthesis de novo. unaffected by exogenously added hypoxanthine, and failure to incorporate hypoxanthine into nucleotides. As expected, loss of HPRT activity is not associated with any significant differences in other enzymes important for purine nucleotide synthesis. These findings, which represent the first direct demonstration of increased purine production in neural tissue deficient in HPRT, are in accordance with data on fibroblasts and lymphoblasts derived from patients with the Lesch-Nyhan syndrome (3, 4) and, thus, the mutant neuroblastoma cells biochemically mimic the cells of these patients. Whether the defect in the neuroblastoma cells represents a mutation in a structural gene or an inherited change in regulation of HPRT activity has yet to be resolved.
Is HPRT deficiency associated with any defect in neural properties? To date, 6-SGua-resistant neuroblastoma clones, including N4TG1, have shown no qualitative differences from parental lines in activity of acetylcholinesterase, neurite formation, silver impregnation, electrical excitability (12, 13), or synthesis of acetylcholine (37) . It should now be possible to study neurotransmitter metabolism and membrane chemosensitivity in HPRT-deficient mutant clones derived from parent neuroblastoma lines of the appropriate phenotype (37) . The possible role of HPRT deficiency in glial cell functions and neuronal-glial interactions may now also be explored with a 6-SGua-resistant clone derived from rat glioblastoma lines (37) .
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